An interventional study of Kidney cooling device in Kidney Transplant; Complications and Delayed Graft Function, sponsored by Thomas Skinner. Not yet recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-04-21.
Sponsored by Thomas Skinner · Not applicable, Interventional, and Device feasibility
Avoiding warm ischemia time during vascular anastomosis of the renal allograft is important to prevent damage. The investigators are studying a cooling device that may control the temperature of the renal allograft during transplant surgery; attempting to keep temperatures at or below 5°C for at least 60 minutes. If found effective, this could eliminate warm ischemia and potentially prevent damage to transplanted kidneys.
Warm ischemia can damage a renal allograft in many different ways often leading to early failure of the kidney transplant and sometimes even death of the transplant recipient. For this reason every effort is made to keep the allograft cold during the removal and transportation, and protocols have been developed to ensure this. Although kidneys are kept below 5°C during transportation, they re-warm rapidly during the transplant surgery. On average, kidneys are exposed to 40 or more minutes of dangerously warm temperatures during transplant surgery.
To avoid damage, it is important to reduce the amount of time it is exposed to warm temperatures. Currently, there are no devices or standardized protocols available to ensure a kidney stays cold during the transplant surgery.
The Principal Investigator has developed Kidney Skinn, a device that may control the temperature of the renal allograft during transplant surgery; keeping allograft temperatures at or below 5°C for at least 60 minutes. If found effective, this could eliminate warm ischemia and potentially prevent damage to transplanted kidneys. The device may also potentially provide retraction and support for the kidney during the transplant operation, making the surgery easier to perform. Additionally, the device may be found to be easily removed once the transplant is complete.
A previous study was conducted with the Kidney Skinn in animals; the next step is to investigate whether the device can perform in the human clinical setting. This study will be done in 2 steps. Part A: a series of consecutive consenting patients to determine device initial safety, and Part B: a single-centre randomized-controlled pilot study of kidney transplant recipients.
83 studies on the registry are indexed under Delayed Graft Function; 15 are open to participants now.
This study's planned enrollment of 45 is below the median of 90 across 62 interventional studies indexed under Delayed Graft Function.
Browse Delayed Graft Function studies →This is the only study on the registry with Thomas Skinner as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
All patients in Part A, and those randomized to the Kidney Skinn arm in Part B, will receive transplant surgery in the traditional fashion with the exception that the renal allograft will be placed in the cooling device at the initiation of the vascular anastomosis. Cold saline irrigation flowing through the device will be used to maintain renal hypothermia for the duration for the vascular anastomosis. After the vascular clamps are released, the device will be removed.
Device: Kidney cooling device
Standard transplant surgery per site practice
renal cooling device designed to maintain renal hypothermia at or below 5ºC for 60 minutes.
Also known as: Kidney Skinn
Part A: Device design is deemed suitable to move into the traditional feasibility stage (Part B of protocol)
The Kidney Skinn cooling device can be utilized during vascular anastomosis, and the ability of the device to maintain surface and core temperatures of transplant kidneys at \<5ºC for the duration of the vascular anastomosis.
Time frame: 6 months
Part B: To determine the feasibility of a trial using the Kidney Skinn cooling device to usual care to ameliorate warm ischemia time during kidney transplantation
Feasibility Outcomes will include the following: 1. Ability to randomize \>60% of eligible patients 2. \>75% of patients randomized to the Kidney Skinn arm use the device 3. 70% of patients randomized to the device (Kidney Skinn) achieve a renal allograft surface temperature of \<5C for the duration of the vascular anastomosis.
Time frame: 2 years
Proportion of patients who develop delayed graft function (need for dialysis in the first week after transplantation) compared with usual care
Delayed Graft function as defined by the need for dialysis in the first 7 post operative days
Time frame: 7 days
Difference in ischemia-reperfusion injury biomarker levels between the intervention and control groups
Urine and serum biomarkers for ischemia-reperfusion injury will be collected at specific key time points pre and post transplantation on all Part B trial participants. Specifically, urine and serum samples for unique markers of kidney injury (KIM-1 \& NGAL), inflammation (TNFR1, MCP-1) and fibrosis (suPAR, YKL 40).
Time frame: 7 days
Serum creatinine level at discharge from initial hospitalization for transplantation
Local laboratory serum creatinine drawn per standard of care on all renal transplant recipients on day of discharge
Time frame: 5-7 days
Differences in achieved renal allograft surface temperature comparing the Kidney Skinn (intervention arm) versus usual care (control arm)
For each surgery, K-type 30 gauge thermocouples (each less than 0.25mm in external diameter) will be used in the renal allograft at a depth of 5 mm and 15 mm. This will be to measure surface (cortical) and core (medullary) temperatures, respectively.
Time frame: 60 minutes
Plan to share: No — This is a pilot study
No publications or documents are linked to this record.
Start is estimated for Oct 2023; primary completion for Jan 2026, 27 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.